Allergan, Inc. (AGN) announced the U.S. Food and Drug Administration's approval of JUVEDERM XC, a new formulation of the currently FDA-approved JUVEDERM dermal filler and the latest advancement in hyaluronic acid, or HA, dermal fillers. Allergan's new JUVEDERM formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds that appear around the nose and mouth.
The JUVEDERM XC formulation with 0.3% preservative-free lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic.
The company noted that the FDA approval of JUVEDERM XC was based on data from a multicenter, double-blind, randomized clinical trial. JUVEDERM XC was found to be more effective in reducing procedural pain during correction of facial wrinkles and folds while maintaining a similar safety and effectiveness profile to the non-lidocaine formulation of JUVEDERM.
Following FDA's approval, the new formulation of JUVEDERM with lidocaine is available for ordering nationwide.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.